Continuous Glucose Monitor
Wearable sensor providing real-time glucose data to optimize metabolic health and personalize nutrition.
Evidence Summary
Continuous glucose monitoring (CGM) began as a diabetes tool and is now widely used for metabolic optimization in people without diabetes, where the strongest recent evidence is for detecting early metabolic dysfunction and guiding lifestyle change. A 2026 systematic review and meta-analysis (Journal of Diabetes Science and Technology; 10 studies, 1,657 participants) found CGM metrics reliably separate prediabetes from normoglycemia: 24-hour mean glucose was higher by 7.9 mg/dL (95% CI 6.3 to 9.5), glycemic variability (MAGE) by 9.4 mg/dL (95% CI 4.3 to 15.3), and time-above-range by 5.7 percentage points (95% CI 1.0 to 10.3). A 2026 systematic review of CGM in non-diabetic populations (European Journal of Medical Research; 23 studies, 1,074 participants) reported CGM-guided feedback was associated with lower mean glucose (standardized mean difference -0.54, 95% CI -1.02 to -0.07), with benefit concentrated in people with prediabetes rather than already-healthy normoglycemic individuals. A 2025 systematic review (Sensors; 32 studies) catalogued how lifestyle levers move CGM readings: low-glycemic-index meals, post-meal walking, and interval exercise blunt glucose excursions, while breakfast skipping and short-term inactivity raise them, supporting CGM's role in personalized nutrition and cardiovascular prevention. Overall evidence quality is moderate and long-term outcome data in healthy people remain limited. Educational information, not a diagnosis or treatment recommendation.
Evidence Scale
Mechanism of Action
A subcutaneous sensor measures interstitial glucose every 1-5 minutes and streams continuous readings to an app. This reveals postprandial (after-meal) spikes, overnight glucose, and day-to-day glycemic variability that single fasting or HbA1c measurements miss. Variability metrics such as MAGE (mean amplitude of glycemic excursions) and time-above-range appear to rise across the spectrum from normoglycemia to prediabetes, making CGM a sensitive window into early metabolic change and a real-time feedback loop for diet, activity, sleep, and stress.
Who Is This For?
Metabolic optimization, prediabetes, diabetes, personalized nutrition, athletic performance, longevity monitoring.
Protocol & Dosing
Dose
2-week sensor wear. Replace as directed.
Frequency
Continuous
Duration
2-4 week learning periods, periodic check-ins
Protocol Summary
Apply the sensor to the back of the upper arm (Abbott Libre) or abdomen (Dexcom) and wear continuously for a 10-14 day sensor cycle. Review responses in the app, focusing on postprandial peaks and glycemic variability rather than isolated values. A 2-4 week learning period is typically enough to map personal responses to specific meals, exercise, sleep, and stress; periodic re-checks track progress. Interpret trends with a clinician.
Latest Evidence
2025-2026: CGM's clearest use in healthy people is early detection and behavior change
A 2026 systematic review and meta-analysis (Journal of Diabetes Science and Technology; 10 studies, 1,657 participants) found CGM metrics reliably separate prediabetes from normoglycemia: 24-hour mean glucose higher by 7.9 mg/dL (95% CI 6.3-9.5), glycemic variability (MAGE) by 9.4 mg/dL (95% CI 4.3-15.3), and time-above-range by 5.7 percentage points (95% CI 1.0-10.3) — differences that fasting glucose or HbA1c alone can miss.
A 2026 systematic review of CGM in non-diabetic populations (European Journal of Medical Research; 23 studies, 1,074 participants) linked CGM-guided feedback to lower mean glucose (SMD -0.54, 95% CI -1.02 to -0.07), with benefit concentrated in prediabetes rather than already-healthy people. A 2025 review (Sensors; 32 studies) showed how lifestyle moves the curve: low-glycemic-index meals, post-meal walking, and interval exercise blunt glucose spikes, while breakfast skipping and a few days of inactivity raise them.
Evidence quality is moderate and long-term outcome data in healthy people are still limited; CGM is best framed as a coaching and early-detection tool, not a diagnosis. Educational information, not medical advice.
Meta-analysis · pooled difference, prediabetes minus normoglycemia · higher = earlier dysglycemia
CGM separates prediabetes from normoglycemia before it becomes diabetes
Bars show the pooled difference in each CGM metric between people with prediabetes and those with normal glucose; whiskers are 95% confidence intervals. All three differences exclude zero (statistically significant). 24-hour mean glucose and glycemic variability (MAGE) are in mg/dL; time-above-range is in percentage points. Source: a 2026 systematic review and meta-analysis of 10 studies and 1,657 participants (Journal of Diabetes Science and Technology). This shows CGM can flag early metabolic change, not that any individual has a condition. Educational information, not medical advice.
Related on Peak Human
GLP-1 Agonists
Metabolic pharmacotherapy CGM data helps monitor.
Intermittent Fasting
A lever CGM can show flattening your glucose curve.
Berberine
A supplement studied for glucose control.
Diabetes & Prediabetes
Where CGM's evidence base is strongest.
Weight Loss
Glycemic feedback supports metabolic goals.
Advanced Testing
Clinician-guided metabolic assessment.
Oral GLP-1
A metabolic product in the Peak Human shop.
Key references: CGM metrics distinguish prediabetes from normoglycemia — meta-analysis, J. Diabetes Sci. Technol. (2026) · CGM in non-diabetic populations — systematic review & meta-analysis, Eur. J. Med. Res. (2026) · Non-invasive CGM for cardiovascular prevention in people without diabetes — systematic review, Sensors (2025)
Interactions & Precautions
Contraindications
- None for monitoring
- MRI with some sensors
Potential Risks
- •Cost
- •Data overload
- •Potential anxiety
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Game-changer for metabolic awareness. Track glucose variability (MAGE, time-in-range), not just absolute values. In people without diabetes the biggest wins are behavioral: 2025 evidence shows post-meal walks and lower-glycemic meals visibly flatten curves. Watch for over-interpretation and data anxiety; frame CGM as a coaching tool over a 2-4 week learning period.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation